Australia's Race Oncology jumps on approval for breast cancer trial

Racura Oncology

01/02/2023 02:24

** Shares of Race Oncology Ltd  RAC.AX  rise as much as 5.9%
to A$1.99, seeing their best day since Jan 17, if gains hold
    ** Precision oncology firm says received human ethics
approval for observational cardioprotection breast cancer trial
stage of Zantrene®
    ** Stock down 6.5% this year, as of last close
 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com;))